BioSpace News Archive

ivWatch, LLC, inventor of the first and only continuous IV infiltration detection technology, announces the appointment of Kathy Cox to Chief Financial Officer.

According to The Insight Partners market research study titled ‘Musculoskeletal Diseases Treatment Market to 2025 – Global Analysis and Forecasts by Disease and Imaging Modality.

The report highlights trends prevailing in the global rehabilitation robots market and the factors driving market along with those that act as hindrances.

The market is estimated to grow with a CAGR of 13.0% from 2018-2025.

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the “Company”), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced the closing of its previously announced underwritten initial public offering of 3,000,000 units,

BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced that it was awarded a contract from Biomedical Advanced Research and Development Authority

Irvine-based Biogennix, an advanced osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, is celebrating the 10th anniversary of its first clinical case.

electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), today provided a corporate update and reported financial results for its fiscal year ended March 31, 2021.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that is has commenced an underwritten public offering of 14,000,000 shares of its common stock. In connection with this offering